- Home
- GROV vs KPTI Comparison
GROV vs KPTI Comparison
Compare GROV & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GROV | KPTI |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 36.7M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GROV | KPTI |
|---|---|---|
| Price | $1.12 | $0.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 43.5K | ★ 5.6M |
| Earning Date | 11-10-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,716,000.00 | $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.14 | $27.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $0.86 | $0.09 |
| 52 Week High | $1.55 | $10.99 |
Technical Indicators
Market Signals| Indicator | GROV | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 64.66 | 29.59 |
| Support Level | $1.06 | N/A |
| Resistance Level | $1.17 | $2.16 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 100.00 | 0.89 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).